# HCRN GU14-182 (NCT02500121)

> Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: metastatic urothelial cancer after first-line chemotherapy

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02500121
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Matthew Galsky
- Conditions: Urothelial Carcinoma; Bladder Cancer
- Interventions: Placebo; Pembrolizumab
- Enrollment: 108
- Primary outcome: Progression-free Survival (PFS)

## Indexed commentary on HCRN GU14-182 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=hcrn-gu14-182-nct02500121